Patents by Inventor Melanie H. Cobb
Melanie H. Cobb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040009175Abstract: Compositions and methods are provided for potentiating the activity of the mitogen-activated protein kinase p38. In particular the mitogen-activated protein kinase kinase MEK6, and variants thereof that stimulate phosphorylation of p38 are provided. Such compounds may be used, for example, for therapy of diseases associated with the p38 cascade and to identify antibodies and other agents that inhibit or activate signal transduction via p38.Type: ApplicationFiled: May 27, 2003Publication date: January 15, 2004Inventors: Melanie H. Cobb, Michele Hutchison, Zhu Chen, Kevin Scott Berman
-
Patent number: 6586242Abstract: Compositions and methods are provided for potentiating the activity of the mitogen-activated protein kinase p38. In particular the mitogen-activated protein kinase kinase MEK6, and variants thereof that stimulate phosphorylation of p38 are provided. Such compounds may be used, for example, for therapy of diseases associated with the p38 cascade and to identify antibodies and other agents that inhibit or activate signal transduction via p38.Type: GrantFiled: November 27, 2000Date of Patent: July 1, 2003Assignee: Board of Regents, The University of Texas SystemInventors: Melanie H. Cobb, Michele Hutchison, Zhu Chen, Kevin Scott Berman
-
Patent number: 6303358Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.Type: GrantFiled: July 7, 1997Date of Patent: October 16, 2001Assignees: Regeneron Pharmaceuticals, Inc., University of TexasInventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
-
Patent number: 6297035Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.Type: GrantFiled: September 17, 1997Date of Patent: October 2, 2001Assignees: Regeneron Pharmaceuticals, Inc., University of TexasInventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
-
Patent number: 6277963Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.Type: GrantFiled: September 18, 1997Date of Patent: August 21, 2001Assignees: Regeneron Pharmaceuticals, Inc., University of TexasInventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
-
Patent number: 5914261Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.Type: GrantFiled: June 2, 1995Date of Patent: June 22, 1999Assignees: Regeneron Pharmaceuticals, Inc., Board of Regents, University of Texas SystemInventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
-
Patent number: 5872006Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.Type: GrantFiled: June 5, 1995Date of Patent: February 16, 1999Assignees: Regeneron Pharmaceuticals, Inc., Board of Regents The University of Texas SystemInventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
-
Patent number: 5776751Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.Type: GrantFiled: June 5, 1995Date of Patent: July 7, 1998Assignees: Regeneron Pharmaceuticals, Inc., Board of Regents, Univ Of TexasInventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
-
Patent number: 5595904Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.Type: GrantFiled: January 3, 1994Date of Patent: January 21, 1997Assignees: Board of Regents, Univ. of Texas, Regeneron Pharmaceuticals, Inc.Inventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos